Clinical trials: Prostatic Neoplasm, open to volunteers
Prostate Cancer (Post Prostatectomy), Radiotherapy; Image-Guided
Radiotherapy After Prostatectomy for Node Positive Prostate Cancer
The goal of this clinical trial is to evaluate whether the addition of pelvic radiotherapy to androgen deprivation therapy (ADT) can delay disease progression and improve survival outcomes in patients with pathologically…
- Conditions
- Prostate Cancer (Post Prostatectomy), Radiotherapy; Image-Guided, Prostate Cancer Non-Metastatic, Androgen Deprivation Therapy
- Trial name
- RADVAN (NCT07477626)
- Testing
- Androgen Deprivation Therapy (ADT), radiotherapy
- Where
- 13 sites in China
- Volunteers
- 372 people
- Sponsor
- Sun Yat-sen University
Non Small Cell Lung Carcinoma NSCLC, Head and Neck Cancer
A Study of a New PET Scanner in People With Cancer
The researchers are doing this study to test the capabilities of a new total-body PET scanner called the Biograph Vision Quadra.
- Conditions
- Non Small Cell Lung Carcinoma NSCLC, Head and Neck Cancer, Prostate Cancer
- Trial name
- NCT07690917
- Testing
- Biograph Vision Quadra scanner, PET/CT
- Where
- 7 sites in United States
- Volunteers
- 90 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Castration-resistant Prostatic Neoplasms
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in Part 1 in combination with best supportive care (BSC) and in…
- Trial name
- KLK2-comPAS (NCT07164443)
- Testing
- Pasritamig, Best Supportive Care (BSC), JNJ-87189401
- Where
- 174 sites in United States, Australia and 15 more
- Volunteers
- 1,203 people
- Sponsor
- Janssen Research & Development, LLC
Prostatic Neoplasms, Castration-Resistant
Fractionated Stereotactic Radiotherapy Plus Second-generation Antiandrogen for Oligometastatic Castration-resistant Prostate Cancer Patients.
The objectives of the study are to analyze the results obtained in survival, safety and quality of life after the combination of SBRT plus second-generation antiandrogen in patients diagnosed with metastatic castration-resistant…
- Trial name
- OLIGORESIST (NCT07717268)
- Testing
- Xtandi, Zytiga® (Abiraterone Acetate), SBRT
- Where
- 15 sites in Spain
- Volunteers
- 51 people
- Sponsor
- Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic
Prostate Cancer
Dose Optimization and Diagnostic Performance in Prostate Cancer (SPARROW [Staging Prostate Cancer With Advanced RM2 Radiotracer Oncologic Workup])
This is an open-label, nonrandomized, multicenter study conducted in two sequential parts: an initial Phase 2 Dose Optimization Period followed by the Phase 3 Diagnostic Performance Period.
- Trial name
- SPARROW (NCT07831824)
- Testing
- [68Ga]-LNTH-2401
- Where
- United States
- Volunteers
- 408 people
- Sponsor
- Lantheus Medical Imaging
Metastatic Castration-resistant Prostate Cancer
Study of Re-treatment With [177Lu]Lu-PSMA in Men With Metastatic Castration Resistance Prostate Cancer
Prostate cancer is the third leading cause of cancer-related death in men in the United States and Europe. The treatment of metastatic castration-resistant prostate cancer (mCRPC) has evolved with the arrival of the radioligand…
- Trial name
- ReaLuP (NCT06866938)
- Testing
- [177Lu]Lu-PSMA-617 (Pluvicto, Novartis)
- Where
- 16 sites in France
- Volunteers
- 58 people
- Sponsor
- Hospices Civils de Lyon
Prostate Cancer (Adenocarcinoma), Low and Intermediate Risk Prostate Cancer
Micro-ultrasound-Guided Focal Laser Ablation for Intermediate-Risk Prostate Cancer: Safety & Effectiveness
This clinical research study is intended to show that Micro-Ultrasound Guided Focal Laser Ablation (MicroUSgFLA) is a safe procedure that can significantly postpone or eliminate the need for patients with intermediate-Risk…
- Trial name
- MicroUSgFLA (NCT07339943)
- Testing
- 6 month, prospective, interventional single-arm safety and effectiveness study, The TRANBERG|CLS Thermal therapy
- Where
- Canada
- Volunteers
- 7 people
- Sponsor
- University Health Network, Toronto
Prostate Cancer, mHSPC
Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer
The goal of this phase 3 clinical trial is to determine the clinical effectiveness and cost effectiveness of using lower doses of Androgen Receptor Pathway Inhibitors (ARPI) to treat patients with prostate cancer that has spread…
- Conditions
- Prostate Cancer, mHSPC, mCRPC
- Trial name
- ENHANCE (NCT07751133)
- Testing
- Abiraterone, Apalutamide, Enzalutamide or Darolutamide (ARPI therapy) (per standard of care) therapy
- Where
- 2 sites in United Kingdom
- Volunteers
- 1,500 people
- Sponsor
- University College, London
Clinical Suspicion of Prostate Cancer
Fully Hybrid 18F-PSMA PET/MRI as One-stop Approach for the Diagnosis of Clinically Significant Prostate Cancer.
This project aims to evaluate the role of fully hybrid PET/MRI with 18FPSMA and multiparametric MR imaging (mpMRI) as one-stop approach for the diagnosis of clinically significant prostate cancer (csPCa).
- Trial name
- RF2021-1237227 (NCT06305390)
- Testing
- PET/MRI
- Where
- Italy
- Volunteers
- 167 people
- Sponsor
- IRCCS San Raffaele
CNS Cancer, Head and Neck Cancer
Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors
The goal of this clinical research trial is to study the use of differing investigational doses and scheduling for Proton Therapy for tumors previously treated with radiation therapy.
- Conditions
- CNS Cancer, Head and Neck Cancer, GI Cancer, Gynecologic Cancer
- Trial name
- ReRT (NCT05313191)
- Testing
- Pencil Beam Scanning Proton Therapy
- Where
- United States
- Volunteers
- 1,800 people
- Sponsor
- The New York Proton Center
Prostate Cancer
TULIP ReTrain Study
This prospective clinical study aims to retrain and validate the PCaVision AI algorithm for the detection and localization of clinically significant prostate cancer (csPCa) using multiparametric ultrasound (mpUS) with two…
- Trial name
- TULIP ReTrain (NCT06974539)
- Testing
- Multiparametric ultrasound with contrast (Sonovue and Optison)
- Where
- Netherlands
- Volunteers
- 212 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Prostatic Cancer
Cleaning the Biopsy Needle in TRUS Bx
Prostate cancer(PCa) is the second most common cancer diagnosed in men. Clinical suspicion of PCa is mentioned in patients with digital rectal examination findings and elevated serum PSA.
- Trial name
- NCT06836271
- Testing
- Isopropyl Alcohol, Povidine-iodine, formaldehit
- Volunteers
- 200 people
- Sponsor
- Hitit University
mCRPC (Metastatic Castration-resistant Prostate Cancer), Prostate Cancer
A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
This is a dose-finding study to assess the safety and preliminary antitumor activity of Pocenbrodib alone or with darolutamide in patients with metastatic castration-resistant prostate cancer (mCRPC)
- Trial name
- P300 (NCT06785636)
- Testing
- Pocenbrodib, Pocenbrodib and Darolutamide
- Where
- 19 sites in United States
- Volunteers
- 120 people
- Sponsor
- Pathos AI, Inc.
Prostate Cancer Metastatic Disease
Radiotherapy or Surgery Combined With Intense Androgen Deprivation Therapy for mCRPC
This multi-center randomized controlled phase II trial was carried out in several hospitals in China to evaluate the efficacy and safety of radiotherapy or radical prostatectomy combined with intense androgen deprivation therapy…
- Trial name
- NCT06992232
- Testing
- Intense androgen deprivation therapy, Radiation Therapy, radical prostatectomy
- Where
- China
- Volunteers
- 144 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma
Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study
This phase II trial studies how well giving testosterone at levels higher than normally found in the body (supraphysiological) works to enhance chemotherapy treatment, and Lutetium 177Lu-prostate specific-membrane antigen…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
- Trial name
- NCT06039371
- Testing
- Biopsy Procedure, Biospecimen Collection, Bone Scan
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- University of Washington
Prostate Cancer
Water Vapor Ablation for Grade Group 3 Prostate Cancer
The goal of this study is to evaluate the safety and effectiveness of the Vanquish Water Vapor Ablation System ("Vanquish") in participants with Grade Group 3 (GG3) intermediate-risk prostate cancer.
- Trial name
- VAPOR 3 (NCT07652164)
- Testing
- Water Vapor Ablation
- Volunteers
- 120 people
- Sponsor
- Francis Medical Inc.
Diabetes, Prostate Cancer
Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study
The goal of this clinical research study is to determine how well a tirzepatide-assisted weight loss program works before a prostatectomy in patients with intermediate risk prostate cancer
- Trial name
- NCT06759701
- Testing
- Tirzepatide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Urethral Internal Sphincter Morphology, Benign Prostatic Hyperplasia
MRI-DTI Assessment of Urethral Internal Sphincter Ring and Prostate Base Morphology
This is a single-center, observational imaging study designed to evaluate the in vivo morphology of the male urethral internal sphincter ring using magnetic resonance diffusion tensor imaging (MRI-DTI) fiber tracking and to…
- Conditions
- Urethral Internal Sphincter Morphology, Benign Prostatic Hyperplasia, Prostate Cancer
- Trial name
- NCT07694752
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Jiangsu Taizhou People's Hospital
Metastatic Castration-resistant Prostate Cancer
177Lu-P17-087/177Lu-P17-088 in Patients With Metastatic Castration-resistant Prostate Cancer
This is a pilot study to assess the safety and measure image-based absorbed dose of 177Lu-P17-087/177Lu-P17-088 in patients with metastatic castration-resistant prostate cancer (mCRPC) who will undergo radioliagnd therapy using…
- Trial name
- NCT05603559
- Testing
- 1.1 GBq (30 mCi) of 177Lu-P17-087, 1.1 GBq (30 mCi) of 177Lu-P17-088
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking Union Medical College Hospital
Prostate Cancer
Training on Systemic and Organ Spec. PM in PC
This research is being done to assess the impact of a supervised and structured strength and conditioning program on cardiac remodeling in participants with prostate cancer undergoing treatment with external beam radiation…
- Trial name
- NCT07768917
- Testing
- Exercise
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.